web analytics
19.8 C
Munich
Thursday, August 11, 2022

Sunshine Biopharma, Inc. (OTCMKTS:SBFM) The Bull Has Awoken

Sunshine Biopharma, Inc. (OTCMKTS:SBFM) is moving up in a hurry on heavy accumulation, breaking out over current levels and surging over a penny on massive volume. The stock is quickly attracting legions of shareholders who continue to bid SBFM higher.

It’s easy to get excited about SBFM here; the Company recently filed a patent application for a new coronavirus COVID-19 Treatment. Sunshine Biopharma’s patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease (Mpro), an enzyme that is essential for viral replication. The small molecules covered by the patent application were computer modelled and designed by Dr. Steve N. Slilaty, CEO of Sunshine Biopharma.

Sunshine Biopharma, Inc. (OTCMKTS:SBFM) is a fully integrated pharmaceutical company offering generic and proprietary drugs for the treatment of cancer and other acute and chronic indications. Since inception, SBFM proprietary drug development activities have been focused on the development of a small molecule called Adva-27a for the treatment of aggressive forms of cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer cells including Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells. Sunshine Biopharma is direct owner of all issued and pending worldwide patents pertaining to Adva-27a including U.S. Patents Number 8,236,935 and 10,272,065.

Microcapdaily has been covering SBFM for many years; on April 4, 2016 we covered the stock commenting “Sunshine Biopharma, Inc. (OTCMKTS:SBFM) is making an explosive move up on accelerating volume since reversing off $0.0121 lows last week. The stock does have a history of big moves running from well under $0.25 to highs over $1.25 in 2011.

To Find out the inside Scoop on SBFM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

SBFM

On June 3 SBFM announced it has filed a patent application in the United States for a new treatment for Coronavirus infections, including COVID-19. Sunshine’s patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease (Mpro), an enzyme that is essential for viral replication. The small molecules covered by the patent application were computer modelled and designed by Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. The patent application has a priority date of May 22, 2020.

“The causative agent of the current COVID-19 global pandemic is Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), one of several strains of Coronavirus capable of infecting humans and causing serious illness. SARS-CoV-2 produces several functional proteins in infected human cells by cleaving them from two overlapping viral ‘polyproteins,’ pp1a and pp1ab. One of these functional proteins is a cysteine protease referred to as the main protease (Mpro, also called 3CLpro and nsp5). Mpro cleaves the viral ‘polyproteins’ at a number of specific sites thereby generating a multi-subunit protein complex termed ‘viral replicase-transcriptase’. Because of its functional indispensability in viral replication, Mpro is an attractive drug target for the development of a treatment for COVID-19 and other Coronavirus infections,” said Dr. Slilaty.

Sunchinse Biopharma has the right people behind it; its CEO Dr. Slilaty is an accomplished scientist and a highly skilled business executive. He received his Bachelor of Science degree in Genetics and Biochemistry from Cornell University and his Ph.D. in Molecular Biology & Biochemistry from the University of Arizona. Dr. Slilaty is a leader in the bioscience industry and is referenced in editorials, reviews and textbooks. His extensive contributions to science included the discovery of a new class of enzymes (IUBMB Enzyme: EC 3.4.21.88) and the development of key technology for the Human Genome Project (TrueBlue Cloning System). With a passion for medicine, he founded three biotech companies and took one public. The company he took public, Genomics One Corporation reached $1 billion market cap. At Sunshine Biopharma Dr. Slilaty is working with the same determination as he pioneers a path towards the discovery of ground breaking drugs for the treatment of aggressive forms of cancer.

We have a Monster Pick Coming. Subscribe Right Now!

Currently running up the charts SBFM is an exciting story developing in small caps; the Company recently filed a patent application for a new coronavirus COVID-19 Treatment. Sunshine Biopharma’s patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease (Mpro), an enzyme that is essential for viral replication. The small molecules covered by the patent application were computer modelled and designed by Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. SBFM has been around for years and has seen some highly explosive moves up in the past so when it heats up, long term speculators pay attention. We will be updating on SBFM when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with SBFM.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in SBFM either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.